StockData
Amgen Inc logo

Amgen Inc (AMGN) KPIs and segments

AMGNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Nov 4, 2026Score 17/3026% above fair value
$443.89−14.04 (-3.07%)

Close on Nov 18, 2026Market cap $239.98BP/E 25.7Yield 2.18%

KPI & bộ phận

Chỉ số vận hành và bộ phận làm nên hoạt động của Amgen · năm tài chính kết thúc Calendar fiscal year ending December 31 (FY2025 ended December 31, 2025; Q2 2026 ended June 30, 2026)

Nhìn nhanh KPI của Amgen: 76 chỉ số vận hành, trong đó có Total Revenues — Worldwide, Total Product Sales — Worldwide và Repatha (evolocumab, lấy từ 164 tài liệu nguồn, cùng doanh thu theo bộ phận, sản phẩm và khu vực từ hồ sơ SEC. Mỗi số đều dẫn tới tài liệu gốc. Tất cả chỉ số hiện cả bảng; Cốt lõi chỉ giữ bộ phận và KPI nổi bật. Bảng bộ phận còn có cách xem lũy kế 12 tháng.

Biểu đồ đang trống. Tick vào ô cạnh bất kỳ chỉ số nào ở bảng dưới để vẽ — tick nhiều chỉ số để so sánh trên cùng một biểu đồ.

Bộ phận, KPI nổi bật và mọi chỉ số vận hành từ hồ sơ, thông cáo kết quả và bản trình bày.

Thêm vào biểu đồChỉ số
Q2 2026
Q1 2026
Q4 2025
Q3 2025
Q2 2025
Q1 2025
Q4 2024
Q3 2024
Q2 2024
Q1 2024
Q4 2023
Q3 2023
Product sales($M)2
9,5378,2189,3679,1378,7717,8738,7168,1518,0417,1187,8336,548
United States($M)
6,9905,7736,9196,7516,3245,6626,5095,9795,8404,9735,8704,691
ROW($M)
2,5472,4452,4482,3862,4472,2112,2072,1722,2012,1451,9631,857
Other products($M)2
1,6971,5282,0731,8531,3801,4751,5681,3631,3261,3731,3761,004
United States($M)
1,2831,1311,5301,4089901,1091,1799589379631,036675
ROW($M)
414397543445390366389405389410340329
Repatha($M)2
953876794696656606567532517417406
United States($M)
510465442361343315281270273201183
ROW($M)
443411352335313291286262244216223
Prolia($M)2
7597271,0541,1391,1221,0991,1651,0451,1659991,107986
United States($M)
478461707806745720775683770657746673
ROW($M)
281266347333377379390362395342361313
EVENITY($M)2
714562599541518442431399391342318307
United States($M)
550431468417395320325289281236239214
ROW($M)
1641311311241231221061101101067993
ENBREL($M)2
5803205325806045101,0158259095671,0151,035
United States($M)
5743145245745975041,0088179025611,0051,026
ROW($M)
6686767876109
TEPEZZA($M)2
5764904575605053814604884794244480
United States($M)
5204244095184663654564824784194410
ROW($M)
566648423916461570
Other revenues($M)
517400499420408276370352347329363355
Otezla($M)2
491431625585618437624564544394629567
United States($M)
431352511473512343514460432293526462
ROW($M)
607911411210694110104112101103105
TEZSPIRE($M)2
486343474377342285296269234173177161
United States($M)
486343474377342285296269234173177161
ROW($M)
000000000000
BLINCYTO($M)2
472415413392384370381327264244241220
United States($M)
285221270236270273245237165153148147
ROW($M)
187194143156114971369099919373
Nplate($M)2
430412385457369313337456346317386419
United States($M)
275283265333228201221345214190252322
ROW($M)
15512912012414111211611113212713497
KRYSTEXXA($M)2
4002554353203492363463102942352720
United States($M)
3992554353203492363463102942352720
ROW($M)
100000000000
Aranesp($M)2
352311333357359340308337348349319323
ROW($M)
258234218254252249218232257249212216
United States($M)
9477115103107919010591100107107
XGEVA($M)2
352411447539532566561541562561527519
United States($M)
187228291357347360369373399366382374
ROW($M)
165183156182185206192168163195145145
Vectibix($M)2
338287319284305267246282270247251252
ROW($M)
171151156122161132112150137127135136
United States($M)
167136163162144135134132133120116116
UPLIZNA($M)2
33526217691
United States($M)
31724613282
ROW($M)
1816449
KYPROLIS($M)2
314330359378324372378377376350349
United States($M)
201218225232216236238240234222231
ROW($M)
113112134146108136140137142128118
IMDELLTRA/IMDYLLTRA($M)2
28825813481
United States($M)
23318810779
ROW($M)
5570272
Total Revenues — Worldwide ($M)($M)
10,0548,6189,8669,5579,1798,1499,0868,5038,3887,4478,1966,903
Total Product Sales — Worldwide ($M)($M)5
9,5378,2189,3679,1378,7717,8738,7168,1518,0417,1187,8336,548
Total Product Sales — United States ($M)($M)1
6,9905,7736,9196,7516,3245,6626,5095,9795,8404,9735,8704,691
Total Product Sales — U.S. volume growth YoY (%)(%)
9.0%8.0%13.0%13.0%16.0%34.0%30.0%29.0%
Total Product Sales — Rest of World (ROW) ($M)($M)1
2,5472,4452,4482,3862,4472,2112,2072,1722,2012,1451,9631,857
Total Product Sales — Rest of World (ROW) volume growth YoY (%)(%)
8.0%13.0%16.0%15.0%11.0%18.0%15.0%17.0%
Total Product Sales — Worldwide reported growth YoY (%)(%)
9.0%4.0%7.0%12.0%9.0%11.0%11.0%24.0%20.0%22.0%20.0%5.0%
Total Product Sales — Worldwide volume growth YoY (%)(%)
9.0%14.0%15.0%12.0%10.0%25.0%23.0%
Total Product Sales — Worldwide net selling price change YoY (%)(%)
-2.0%-6.0%-3.0%
Repatha (evolocumab — PCSK9 Inhibitor, Cardiovascular) — Worldwide product sales ($M)($M)2
953876870794696656606567532517417406
Repatha (evolocumab — PCSK9 Inhibitor, Cardiovascular) — Worldwide reported sales growth YoY (%)(%)
37.0%34.0%44.0%40.0%31.0%27.0%45.0%40.0%25.0%33.0%25.0%31.0%
Repatha (evolocumab — PCSK9 Inhibitor, Cardiovascular) — Worldwide volume growth YoY (%)(%)
35.0%31.0%36.0%41.0%41.0%46.0%44.0%35.0%43.0%
EVENITY (romosozumab-aqqg — Postmenopausal Osteoporosis) — Worldwide product sales ($M)($M)1
714562599541518442431399391342318307
EVENITY (romosozumab-aqqg — Postmenopausal Osteoporosis) — Worldwide reported sales growth YoY (%)(%)
38.0%27.0%39.0%36.0%32.0%29.0%36.0%30.0%39.0%35.0%41.0%53.0%
Prolia (denosumab — Postmenopausal Osteoporosis) — Worldwide product sales ($M)($M)2
7597271,0541,1391,1221,0991,1651,0451,1659991,107986
Prolia (denosumab — Postmenopausal Osteoporosis) — Worldwide reported sales growth YoY (%)(%)
-32.0%-34.0%-10.0%9.0%-4.0%10.0%5.0%6.0%13.0%8.0%12.0%14.0%
Prolia (denosumab — Postmenopausal Osteoporosis) — Worldwide net selling price change YoY (%)(%)
-12.0%-10.0%-8.0%-5.0%
Aimovig (erenumab-aooe — Migraine Prevention, legacy standalone disclosure) — Worldwide product sales ($M)($M)3
7894
Aimovig (erenumab-aooe — Migraine Prevention, legacy standalone disclosure) — U.S. product sales ($M)($M)
816872906485867780657388
Aimovig (erenumab-aooe — Migraine Prevention, legacy standalone disclosure) — Rest of World (ROW) product sales ($M)($M)
767565655556
Aimovig (erenumab-aooe — Migraine Prevention, legacy standalone disclosure) — Worldwide reported sales growth YoY (%)(%)
-32.0%-12.0%
TEPEZZA (teprotumumab-trbw — Thyroid Eye Disease) — Worldwide product sales ($M)($M)1
5764904575605053814604884794244480
TEPEZZA (teprotumumab-trbw — Thyroid Eye Disease) — Worldwide reported sales growth YoY (%)(%)
14.0%29.0%-1.0%15.0%5.0%-10.0%3.0%
KRYSTEXXA (pegloticase — Uncontrolled Chronic Gout) — Worldwide product sales ($M)($M)1
4002554353203492363463102942352720
KRYSTEXXA (pegloticase — Uncontrolled Chronic Gout) — Worldwide reported sales growth YoY (%)(%)
15.0%8.0%26.0%3.0%19.0%0.0%27.0%
TAVNEOS (avacopan — ANCA-Associated Vasculitis) — Worldwide product sales ($M)($M)4
15011915210711090818071514437
TAVNEOS (avacopan — ANCA-Associated Vasculitis) — U.S. product sales ($M)($M)
14311414210110377767461454232
TAVNEOS (avacopan — ANCA-Associated Vasculitis) — Rest of World (ROW) product sales ($M)($M)
751067135610625
TAVNEOS (avacopan — ANCA-Associated Vasculitis) — Worldwide reported sales growth YoY (%)(%)
36.0%32.0%88.0%34.0%55.0%76.0%84.0%
TAVNEOS (avacopan — ANCA-Associated Vasculitis) — Worldwide volume growth YoY (%)(%)
55.0%69.0%66.0%
Ultra-Rare Products (RAVICTI, PROCYSBI, ACTIMMUNE, BUPHENYL & QUINSAIR) — Worldwide product sales ($M)($M)4
14998157200183179214188187169164
Ultra-Rare Products (RAVICTI, PROCYSBI, ACTIMMUNE, BUPHENYL & QUINSAIR) — U.S. product sales ($M)($M)
14496144195175171205180175166162
Ultra-Rare Products (RAVICTI, PROCYSBI, ACTIMMUNE, BUPHENYL & QUINSAIR) — Rest of World (ROW) product sales ($M)($M)
5213588981232
Ultra-Rare Products (RAVICTI, PROCYSBI, ACTIMMUNE, BUPHENYL & QUINSAIR) — Worldwide reported sales growth YoY (%)(%)
-19.0%-45.0%-27.0%6.0%-2.0%6.0%30.0%
PROCYSBI (cysteamine bitartrate — Nephropathic Cystinosis) — U.S. sales ($M)($M)1
71475962555761575449
PROCYSBI — Rest of World (ROW) sales ($M)($M)
3121222141
TEZSPIRE (tezepelumab-ekko — Severe Asthma) — Worldwide product sales ($M)($M)2
486343474377342285296269234173177161
TEZSPIRE (tezepelumab-ekko — Severe Asthma) — Worldwide reported sales growth YoY (%)(%)
42.0%20.0%60.0%40.0%46.0%65.0%67.0%67.0%76.0%80.0%
TEZSPIRE (tezepelumab-ekko — Severe Asthma) — Worldwide volume growth YoY (%)(%)
32.0%51.0%48.0%
Otezla (apremilast — Plaque Psoriasis & Psoriatic Arthritis) — Worldwide product sales ($M)($M)2
491431625585618437624564544394629567
Otezla (apremilast — Plaque Psoriasis & Psoriatic Arthritis) — Worldwide reported sales growth YoY (%)(%)
-21.0%-1.0%0.0%4.0%14.0%11.0%-1.0%-1.0%-9.0%1.0%2.0%-10.0%
Otezla (apremilast — Plaque Psoriasis & Psoriatic Arthritis) — Worldwide volume growth YoY (%)(%)
-6.0%-2.0%6.0%4.0%4.0%5.0%5.0%2.0%3.0%1.0%
Enbrel (etanercept — Rheumatoid Arthritis & Psoriasis) — Worldwide product sales ($M)($M)2
5803205325806045101,0158259095671,0151,035
Enbrel (etanercept — Rheumatoid Arthritis & Psoriasis) — Worldwide reported sales growth YoY (%)(%)
-4.0%-37.0%-48.0%-30.0%-34.0%-10.0%-20.0%-15.0%-2.0%-8.0%-6.0%
Enbrel (etanercept — Rheumatoid Arthritis & Psoriasis) — Worldwide net selling price change YoY (%)(%)
-22.0%-15.0%-35.0%-38.0%-19.0%-47.0%-12.0%
PAVBLU (aflibercept-ayyh — Eylea Biosimilar, Retinal Diseases) — Worldwide product sales ($M)($M)2
2872802582131309931
PAVBLU (aflibercept-ayyh — Eylea Biosimilar, Retinal Diseases) — U.S. product sales ($M)($M)
28027625421212699
PAVBLU (aflibercept-ayyh — Eylea Biosimilar, Retinal Diseases) — Rest of World (ROW) product sales ($M)($M)
74414
AMJEVITA / AMGEVITA (adalimumab-atto — Humira Biosimilar) — Worldwide product sales ($M)($M)3
155173174154133136294166133168160152
AMJEVITA / AMGEVITA (adalimumab-atto — Humira Biosimilar) — U.S. product sales ($M)($M)
26412816415328-9303323
AMJEVITA / AMGEVITA (adalimumab-atto — Humira Biosimilar) — Rest of World (ROW) product sales ($M)($M)
129132146138133132141138142138127129
AMJEVITA / AMGEVITA (adalimumab-atto — Humira Biosimilar) — Worldwide reported sales growth YoY (%)(%)
17.0%27.0%-41.0%-7.0%-19.0%84.0%9.0%-11.0%2.0%34.0%30.0%
WEZLANA / WEZENLA (ustekinumab-auub — Stelara Biosimilar) — Worldwide product sales ($M)($M)1
61474444351502151
WEZLANA / WEZENLA (ustekinumab-auub — Stelara Biosimilar) — Rest of World (ROW) product sales ($M)($M)
6143444435272151
BLINCYTO (blinatumomab — CD19 BiTE Immuno-Oncology, ALL) — Worldwide product sales ($M)($M)1
472415413392384370381327264244241220
BLINCYTO (blinatumomab — CD19 BiTE Immuno-Oncology, ALL) — Worldwide reported sales growth YoY (%)(%)
23.0%12.0%8.0%20.0%45.0%52.0%58.0%49.0%28.0%26.0%47.0%55.0%
Vectibix (panitumumab — Metastatic Colorectal Cancer) — Worldwide product sales ($M)($M)2
338287319284305267246282270247251252
Vectibix (panitumumab — Metastatic Colorectal Cancer) — Worldwide reported sales growth YoY (%)(%)
11.0%7.0%30.0%1.0%13.0%8.0%-2.0%12.0%9.0%6.0%5.0%2.0%
Vectibix (panitumumab — Metastatic Colorectal Cancer) — Worldwide volume growth YoY (%)(%)
11.0%23.0%-4.0%4.0%
KYPROLIS (carfilzomib — Relapsed/Refractory Multiple Myeloma) — Worldwide product sales ($M)($M)2
314330351359378324372378377376350349
KYPROLIS (carfilzomib — Relapsed/Refractory Multiple Myeloma) — Worldwide reported sales growth YoY (%)(%)
-17.0%2.0%-6.0%-5.0%0.0%-14.0%6.0%8.0%9.0%5.0%8.0%10.0%
KYPROLIS (carfilzomib — Relapsed/Refractory Multiple Myeloma) — Worldwide volume growth YoY (%)(%)
8.0%
Nplate (romiplostim — Immune Thrombocytopenia) — Worldwide product sales ($M)($M)2
430412385457369313337456346317386419
Nplate (romiplostim — Immune Thrombocytopenia) — Worldwide reported sales growth YoY (%)(%)
17.0%32.0%14.0%0.0%7.0%-1.0%-13.0%9.0%12.0%-12.0%-18.0%45.0%
Nplate (romiplostim — Immune Thrombocytopenia) — Worldwide volume growth YoY (%)(%)
13.0%8.0%9.0%14.0%43.0%
XGEVA (denosumab — Oncology Bone Metastases & Giant Cell Tumor) — Worldwide product sales ($M)($M)1
352411447539532566561541562561527519
XGEVA (denosumab — Oncology Bone Metastases & Giant Cell Tumor) — Worldwide reported sales growth YoY (%)(%)
-34.0%-27.0%-20.0%0.0%-5.0%1.0%6.0%4.0%6.0%5.0%9.0%5.0%
LUMAKRAS / LUMYKRAS (sotorasib — KRAS G12C Non-Small Cell Lung Cancer) — Worldwide product sales ($M)($M)3
1119492969085859885827752
LUMAKRAS / LUMYKRAS (sotorasib — KRAS G12C Non-Small Cell Lung Cancer) — U.S. product sales ($M)($M)
624947575255535355535148
LUMAKRAS / LUMYKRAS (sotorasib — KRAS G12C Non-Small Cell Lung Cancer) — Rest of World (ROW) product sales ($M)($M)
49454539383032453029264
LUMAKRAS / LUMYKRAS (sotorasib — KRAS G12C Non-Small Cell Lung Cancer) — Worldwide reported sales growth YoY (%)(%)
23.0%11.0%8.0%-2.0%6.0%4.0%10.0%88.0%10.0%11.0%8.0%-31.0%
MVASI (bevacizumab-awwb — Avastin Oncology Biosimilar) — Worldwide product sales ($M)($M)3
153150188213191179173195157202188213
MVASI (bevacizumab-awwb — Avastin Oncology Biosimilar) — U.S. product sales ($M)($M)
10696137156142138108136100105127140
MVASI (bevacizumab-awwb — Avastin Oncology Biosimilar) — Rest of World (ROW) product sales ($M)($M)
475451574941655957976173
MVASI (bevacizumab-awwb — Avastin Oncology Biosimilar) — Worldwide reported sales growth YoY (%)(%)
-20.0%-16.0%9.0%9.0%22.0%-11.0%-8.0%-8.0%-20.0%-8.0%2.0%
KANJINTI (trastuzumab-anns — Herceptin Biosimilar, legacy standalone disclosure) — Worldwide product sales ($M)($M)3
4220
KANJINTI (trastuzumab-anns — Herceptin Biosimilar, legacy standalone disclosure) — U.S. product sales ($M)($M)
317
KANJINTI (trastuzumab-anns — Herceptin Biosimilar, legacy standalone disclosure) — Rest of World (ROW) product sales ($M)($M)
1113
KANJINTI (trastuzumab-anns — Herceptin Biosimilar, legacy standalone disclosure) — Worldwide reported sales growth YoY (%)(%)
-33.0%-72.0%
Aranesp (darbepoetin alfa — Nephrology & Oncology Anemia) — Worldwide product sales ($M)($M)1
352311333357359340308337348349319323
Aranesp (darbepoetin alfa — Nephrology & Oncology Anemia) — Worldwide reported sales growth YoY (%)(%)
-2.0%-9.0%8.0%6.0%3.0%-3.0%-3.0%4.0%-5.0%-2.0%-8.0%-10.0%
Neulasta (pegfilgrastim — Febrile Neutropenia) — Worldwide product sales ($M)($M)
179165132928212998110105118239124
Parsabiv (etelcalcetide — Secondary Hyperparathyroidism) — Worldwide product sales ($M)($M)3
101878984928875701061058995
Parsabiv (etelcalcetide — Secondary Hyperparathyroidism) — U.S. product sales ($M)($M)
544349425150393267655759
Parsabiv (etelcalcetide — Secondary Hyperparathyroidism) — Rest of World (ROW) product sales ($M)($M)
474440424138363839403236
Parsabiv (etelcalcetide — Secondary Hyperparathyroidism) — Worldwide reported sales growth YoY (%)(%)
10.0%-1.0%19.0%20.0%-13.0%-16.0%-16.0%-26.0%22.0%15.0%-4.0%-5.0%
EPOGEN (epoetin alfa — Dialysis Anemia, legacy standalone disclosure) — Worldwide product sales ($M)($M)1
193332415550
EPOGEN (epoetin alfa — Dialysis Anemia, legacy standalone disclosure) — Worldwide reported sales growth YoY (%)(%)
-65.0%-34.0%-48.0%-32.0%-52.0%-63.0%
Other Products (Segment Note 2 Aggregate) — Worldwide product sales ($M)($M)2
1,6971,5282,0731,8531,3801,4751,5681,3631,3261,3731,3761,004
Biosimilars Included in Other Product Sales — Worldwide ($M)($M)
19918518915117217121814818317693104
Other Residual Products (8-K Schedule) — Worldwide ($M)($M)3
351315320317334340361281346357175167
Other Residual Products (8-K Schedule) — U.S. ($M)($M)
304263263267278283294228292301137136
Other Residual Products (8-K Schedule) — Rest of World (ROW) ($M)($M)
475257505657675354563831
Other Residual Products (8-K Schedule) — Worldwide growth YoY (%)(%)
5.0%-7.0%-2.0%3.0%-12.0%-14.0%22.0%13.0%16.0%9.0%1.0%
Accrued Sales Deductions Liability — Balance Sheet Ending Reserve ($M)1
Operating Cash Flow — Change in Accrued Sales Incentives & Allowance ($M)($M)
1,117-839-2321,184627486658929-77-316520242
Collaborations — AstraZeneca (TEZSPIRE) Profit Share Recorded in Cost of Sales ($M)1
BeiGene / BeOne Oncology Collaboration — R&D Cost Recovery ($M)1
BeiGene / BeOne Medicines — Amgen Equity Ownership Stake (%)(%)
17.0%17.0%17.0%17.8%18.0%18.0%18.0%
R&D Expense by Stage (10-K MD&A) — Total R&D Expense ($M)($M)1
1,8681,7192,1421,9001,7441,4861,7241,4501,4471,3431,5341,079
R&D Expense Excluding Software (Segment Disaggregation Note 2) ($M)($M)
1,8681,7192,1421,9001,7441,4861,7241,4501,4471,343
Non-GAAP Operating Income ($M)($M)2
4,6123,7214,0064,3054,2933,5994,0334,0443,8733,0783,6603,403
GAAP Operating Income ($M)($M)
3,5142,6662,7202,5262,6561,1782,3112,0471,9099911,2712,021
Non-GAAP Operating Margin as % of Product Sales (%)(%)1
48.4%45.3%42.8%47.1%48.9%45.7%46.3%49.6%48.2%43.2%46.7%52.0%
GAAP Operating Margin as % of Product Sales (%)(%)
36.8%32.4%29.0%27.6%30.3%15.0%26.5%25.1%23.7%13.9%16.2%30.9%
Non-GAAP Cost of Sales ($M)($M)2
1,8741,6031,7901,6621,5511,4201,5361,4541,4061,3401,2781,137
GAAP Cost of Sales ($M)($M)
2,8112,7442,9763,0823,0112,9683,1123,3103,2363,2003,1121,806
Non-GAAP Cost of Sales as % of Product Sales (%)(%)1
19.6%19.5%19.1%18.2%17.7%18.0%17.6%17.8%17.5%18.8%16.3%17.4%
GAAP Cost of Sales as % of Product Sales (%)(%)
29.5%33.4%31.8%33.7%34.3%37.7%35.7%40.6%40.2%45.0%39.7%27.6%
Non-GAAP Research & Development Expense ($M)($M)2
1,8511,7112,1331,8901,6851,4751,6981,4401,4231,3171,4941,070
GAAP Research & Development Expense ($M)($M)
1,8681,7192,1421,9001,7441,4861,7241,4501,4471,3431,5341,079
Non-GAAP R&D Expense as % of Product Sales (%)(%)1
19.4%20.8%22.8%20.7%19.2%18.7%19.5%17.7%17.7%18.5%19.1%16.3%
GAAP R&D Expense as % of Product Sales (%)(%)
19.6%20.9%22.9%20.8%19.9%18.9%19.8%17.8%18.0%18.9%19.6%16.5%
Non-GAAP Selling, General & Administrative Expense ($M)($M)2
1,7171,5831,9371,7001,6501,6551,8191,5651,6861,7121,7641,293
GAAP Selling, General & Administrative Expense ($M)($M)
1,7451,6021,9521,7201,6911,6871,8781,6251,7851,8082,2741,353
Non-GAAP SG&A Expense as % of Product Sales (%)(%)1
18.0%19.3%20.7%18.6%18.8%21.0%20.9%19.2%21.0%24.1%22.5%19.7%
GAAP SG&A Expense as % of Product Sales (%)(%)
18.3%19.5%20.8%18.8%19.3%21.4%21.5%19.9%22.2%25.4%29.0%20.7%
Non-GAAP Total Operating Expenses ($M)($M)2
5,4424,8975,8605,2524,8864,5505,0534,4594,5154,3694,5363,500
GAAP Total Operating Expenses ($M)($M)
6,5405,9527,1467,0316,5236,9716,7756,4566,4796,4566,9254,882
Total Non-GAAP Operating Expense Adjustments ($M)($M)
-1,098-1,055-1,286-1,779-1,637-2,421-1,722-1,997-1,964-2,087-2,389-1,382
Non-GAAP Net Income ($M)($M)5
3,4232,7992,8753,0553,2582,6492,8793,0242,6912,1402,5432,667
Non-GAAP Income Before Income Taxes ($M)($M)
4,0553,2413,4403,7373,7963,1033,3793,4903,1632,5293,0253,178
Non-GAAP Provision for Income Taxes ($M)($M)
632442565682538454500466472389482511
Non-GAAP Effective Tax Rate (%)(%)1
15.6%13.6%16.4%18.2%14.2%14.6%14.8%13.4%14.9%15.4%15.9%16.1%
GAAP Effective Tax Rate (%)(%)
14.2%12.7%12.0%18.0%8.7%12.3%19.8%8.7%6.0%-66.2%10.0%11.1%
Non-GAAP Diluted Earnings Per Share ($/sh)($)1
6.295.155.295.646.024.905.315.584.974.714.96
GAAP Diluted Earnings Per Share ($/sh)($)
4.373.342.455.932.653.201.165.221.381.423.22
Non-GAAP Free Cash Flow (Operating Cash Flow Less CapEx) ($M)($M)
3,4891,4779614,2481,9119804,4003,3142,2214592892,512
Segment Expense Disaggregation (Note 2) — Manufacturing Cost of Sales Excluding Amort & Royalty ($M)($M)5
2,1392,1802,3252,5082,4842,5282,6272,8522,8252,814
Segment Profit Share & Royalty Expense in Cost of Sales ($M)($M)
672564651574527440485458411386
Segment Selling & Marketing Expense ($M)($M)
1,1551,1341,2901,0971,1371,0661,1811,1171,2111,204
Segment General & Administrative Expense ($M)($M)
590468662623554621697508574604
Other Segment Items (Other Operating Expenses & Non-Core Items) ($M)($M)
314-87745-1,642557-562948-1,661445520
Restructuring Charges (legacy standalone disclosure) ($M)($M)
1531
Inventories — Total Net Carrying Value ($M)($M)3
6,2206,1866,2256,3466,5836,7296,9987,3627,9958,7249,5185,026
Inventories — Raw Materials ($M)($M)
1,0821,048915955885841818788884928993849
Inventories — Work in Process ($M)($M)
3,4703,4263,4253,5553,6583,9614,1204,3394,4765,2705,7472,992
Inventories — Finished Goods ($M)($M)
1,6681,7121,8851,8362,0401,9272,0602,2352,6352,5262,7781,185
Property, Plant & Equipment — Total Net Carrying Value ($M)($M)2
8,5478,2167,9137,2206,8556,6816,5436,1566,0976,0025,9415,563
Accumulated Depreciation and Amortization of PP&E ($M)($M)
9,4009,30011,10011,00010,80010,60010,38810,30010,1009,9009,8089,700
Capital Expenditures Paid ($M)($M)
513712642436369411371257238230249248
Goodwill — Carrying Value ($M)($M)1
18,66818,67418,68018,67618,67418,64518,63718,65818,61618,57018,62915,509
Goodwill Foreign Currency Translation Adjustment ($M)($M)
-6-642298-2116-2-109-8
Other Intangible Assets — Total Net Carrying Value ($M)($M)7
20,48721,37922,27623,13924,61425,72427,69928,92030,17231,37232,64113,150
Other Intangible Assets — Total Gross Carrying Value ($M)($M)
55,01655,02955,06055,01155,40755,34856,12256,19356,22156,23056,44735,766
Other Intangible Assets — Total Accumulated Amortization ($M)($M)
34,52933,65032,78431,87230,79329,62428,42327,27326,04924,85823,80622,616
Finite-Lived Intangible Assets — Total Net Carrying Value ($M)($M)6
19,77720,66921,56622,42923,90424,66426,63927,83029,02230,22231,42312,992
Finite-Lived Intangible Assets — Total Gross Carrying Value ($M)($M)
54,30654,31954,35054,30154,69754,28855,06255,10355,07155,08055,22935,608
Finite-Lived Intangible Assets — Total Accumulated Amortization ($M)($M)
34,52933,65032,78431,87230,79329,62428,42327,27326,04924,85823,80622,616
Developed Product Technology Rights — Net Carrying Value ($M)($M)2
19,34320,19421,05121,91923,35524,08126,01727,16428,30129,44130,58212,097
Developed Product Technology Rights — Gross Carrying Value ($M)($M)
47,79347,79847,80547,80348,20147,82448,61148,63648,62148,62548,63129,028
Developed Product Technology Rights — Accumulated Amortization ($M)($M)
28,45027,60426,75425,88424,84623,74322,59421,47220,32019,18418,04916,931
Licensing Agreements — Net Carrying Value ($M)($M)2
329363395385418450483504535567600631
Licensing Agreements — Gross Carrying Value ($M)($M)
3,9023,9033,9173,8753,8753,8753,8753,8643,8643,8643,8653,864
Licensing Agreements — Accumulated Amortization ($M)($M)
3,5733,5403,5223,4903,4573,4253,3923,3603,3293,2973,2653,233
Acquired R&D Technology Rights — Net Carrying Value ($M)($M)2
105112120125131133139147152159166168
Acquired R&D Technology Rights — Gross Carrying Value ($M)($M)
1,4091,4161,4251,4211,4191,3871,3741,4001,3831,3881,3941,377
Acquired R&D Technology Rights — Accumulated Amortization ($M)($M)
1,3041,3041,3051,2961,2881,2541,2351,2531,2311,2291,2281,209
Marketing-Related Intangible Assets — Net Carrying Value ($M)($M)2
00000001534557596
Marketing-Related Intangible Assets — Gross Carrying Value ($M)($M)
1,2021,2021,2031,2021,2021,2021,2021,2031,2031,2031,3391,339
Marketing-Related Intangible Assets — Accumulated Amortization ($M)($M)
1,2021,2021,2031,2021,2021,2021,2021,1881,1691,1481,2641,243
Indefinite-Lived In-Process R&D (IPR&D) Intangible Assets ($M)($M)
7107107107107101,0601,0601,0901,1501,1501,218158
Intangible Asset Amortization Expense ($M)($M)5
8908969001,1001,1001,2001,2001,2001,2001,2001,100693
Estimated Future Intangible Amortization — Year 1 ($M)($M)
3,6003,6003,6003,6003,7003,7004,5004,5004,5004,5004,8002,700
Estimated Future Intangible Amortization — Year 2 ($M)($M)
2,8002,8003,5003,5003,7003,7003,9003,9003,9003,9004,5002,500
Estimated Future Intangible Amortization — Year 3 ($M)($M)
2,3002,3002,8002,8002,9002,8003,9003,9003,9003,9003,9002,100
Estimated Future Intangible Amortization — Year 4 ($M)($M)
2,2002,2002,3002,3002,3002,2002,9002,9002,9002,9003,9002,100
Estimated Future Intangible Amortization — Year 5 ($M)($M)
2,1002,1002,2002,2002,2002,1002,2002,2002,2002,2002,9001,100
Intangible Asset Impairment Charges ($M)($M)
00040008003061068
Total Depreciation and Amortization (Cash Flow Statement) ($M)($M)
1,1121,1161,1321,3071,3411,3871,3971,3961,4001,3991,380895
Level 3 Contingent Consideration Liabilities — Ending Fair Value ($M)($M)
1711731619590104106112107969698
Total Debt — Carrying Value (Current + Noncurrent) ($M)($M)3
57,30457,32354,60454,58756,20457,38160,09960,39862,60064,00064,61360,500
Long-Term Debt — Noncurrent Carrying Value ($M)($M)
51,85951,88650,00552,43453,76054,01356,54956,85457,11760,06163,17059,040
Short-Term Debt & Current Portion of Long-Term Debt ($M)($M)
5,4455,4374,5992,1532,4443,3683,5503,5445,5283,9591,4431,428
Unamortized Debt Discount and Issuance Costs ($M)($M)
1,3171,3291,3061,3171,3311,3451,3601,3731,3891,4041,4201,423
Capital Return — Dividends Declared Per Share ($/sh)4
Dividends Paid Per Share (legacy quarterly disclosure) ($/sh)($)
2.132.13
Total Common Stock Dividends Declared ($M)($M)
01,3622,6401,30801,2802,4871,23601,2081,161
Total Cash Dividends Paid ($M)($M)
1,3621,3581,2831,2821,2801,2791,2051,2101,2091,2081,1401,140
Share Repurchases — Cash Paid for Common Stock Repurchased ($M)1
Share Repurchases — Remaining Board Authorization Available ($M)($M)
6,8006,8006,8006,8006,8006,8006,8007,0007,0007,0007,0007,000
Stock-Based Compensation (SBC) — Total Pre-Tax Expense ($M)($M)
1657512512715785134136157103161104
GAAP Effective Tax Rate (%)(%)
14.2%12.7%18.0%8.7%12.3%8.7%6.0%-66.2%11.1%
Deferred Tax Liabilities (DTL) — Total Gross DTL ($M)1
Net Deferred Tax Liabilities Recognized on Balance Sheet ($M)($M)
1,3011,3441,3661,4581,3861,5101,6161,7111,7801,8622,354
Unrecognized Tax Benefits (UTB Rollforward — IRS Transfer Pricing Dispute) — Ending Gross Balance ($M)2
Unrecognized Tax Benefits Liability Affecting Effective Tax Rate ($M)($M)
2,8442,7642,6902,6162,5112,4192,3492,2802,2053,9644,6804,579
UTB Additions Based on Tax Positions Related to Current Year ($M)($M)
453545456040684040403650
U.S. Personal Consumption Expenditures: Health Care Services — SAAR ($B)
3,790.303,699.903,667.003,614.803,529.803,464.703,417.803,358.203,288.203,244.403,159.403,079.00
Income Statement — Total revenues ($M)($M)17
10,0548,6189,8669,5579,1798,1499,0868,5038,3887,4478,1966,903
Cost of sales ($M)($M)
2,8112,7442,9763,0823,0112,9683,1123,3103,2363,2003,1121,806
Research and development expense ($M)($M)
1,8681,7192,1421,9001,7441,4861,7241,4501,4471,3431,5341,079
Selling, general and administrative expense ($M)($M)
1,7451,6021,9521,7201,6911,6871,8781,6251,7851,8082,2741,353
Restructuring charges ($M)($M)
1531
Total operating expenses ($M)($M)
6,5405,9527,1467,0316,5236,9716,7756,4566,4796,4566,9254,882
Operating income ($M)($M)
3,5142,6662,7202,5262,6561,1782,3112,0471,9099911,2712,021
Interest expense, net ($M)($M)
673657653685694723747776808824821759
Interest and other income, net ($M)($M)
125101979986126116126115153
Other nonoperating income (expense) ($M)($M)
-7375-5532,080-3941,518-7821,830-307-235402685
Income before income taxes ($M)($M)
2,7682,0841,5143,9211,5681,9737823,101794-688521,947
Provision for income taxes ($M)($M)
393265181705136243155271484585217
Net income ($M)($M)
2,3751,8191,3333,2161,4321,7306272,830746-1137671,730
Earnings per share — Basic ($/sh)($)
4.403.375.982.663.225.271.39-0.213.23
Earnings per share — Diluted ($/sh)($)
4.373.345.932.653.205.221.38-0.213.22
Weighted-average basic shares (M)(M)
540540538538538537537536535
Weighted-average diluted shares (M)(M)
544544542541541542541536538
Dividends declared per share ($/sh)($)
02.522.522.382.382.382.252.252.252.252.132.13
Balance Sheet — Total assets ($M)($M)22
95,63992,50490,58690,14187,89789,36791,83990,88390,90792,98097,15490,534
Cash and cash equivalents ($M)($M)
13,98912,0389,1299,4458,0288,81011,9739,0119,3019,70810,94434,741
Marketable securities ($M)($M)
00
Trade receivables, net ($M)($M)
10,2279,1389,5708,4908,7018,1326,7827,3176,9346,7767,2686,145
Inventories ($M)($M)
6,2206,1866,2256,3466,5836,7296,9987,3627,9958,7249,5185,026
Other current assets ($M)($M)
4,5254,1134,1333,6043,4223,2583,2773,0762,9762,8212,6022,565
Total current assets ($M)($M)
34,96131,47529,05727,88526,73426,92929,03026,76627,20628,02930,33248,477
Accumulated depreciation ($M)($M)
-9,400-9,300-11,100-11,000-10,800-10,600-10,388-10,300-10,100-9,900-9,808-9,700
Property, plant and equipment, net ($M)($M)
8,5478,2167,9137,2206,8556,6816,5436,1566,0976,0025,9415,563
Intangible assets, net ($M)($M)
20,48721,37922,27623,13924,61425,72427,69928,92030,17231,37232,64113,150
Goodwill ($M)($M)
18,66818,67418,68018,67618,67418,64518,63718,65818,61618,57018,62915,509
Other noncurrent assets ($M)($M)
12,97612,76012,66013,22111,02011,3889,93010,3838,8169,0079,6117,835
Accounts payable ($M)($M)
2,8652,9352,3672,8383,0102,4061,9082,1472,2671,6281,5901,358
Accrued liabilities ($M)($M)
17,19216,58318,52316,80015,02217,23417,64114,62113,72214,12715,35914,168
Total current liabilities ($M)($M)
25,50224,95525,48921,79120,47623,00823,09920,31221,51719,71418,39216,954
Long-term debt ($M)($M)
51,85951,88650,00552,43453,76054,01356,54956,85457,11760,06163,17059,040
Deferred tax liabilities ($M)($M)
1,3011,3441,3661,4581,3861,5101,6161,7111,7801,8622,354
Other noncurrent liabilities ($M)($M)
2,4452,3652,3782,2232,3362,2102,3492,1992,3632,3572,3262,305
Retained earnings (accumulated deficit) ($M)($M)
-22,275-24,650-25,107-23,800-25,708-27,140-27,590-25,530-27,124-27,870-26,549-24,971
Accumulated other comprehensive income (loss) ($M)($M)
-119-190-258-422-544-231-66-336-155-190-289-126
Total stockholders' equity ($M)($M)
11,6889,1908,6589,6197,4286,2075,8777,5275,9255,0226,2327,656
Total liabilities and stockholders' equity ($M)($M)
95,63992,50490,58690,14187,89789,36791,83990,88390,90792,98097,15490,534
Common shares outstanding at period end (M)(M)
541540539539538538537538537536535535
Cash Flow Statement — Operating cash flow ($M)($M)12
4,0022,1891,6034,6842,2801,3914,7713,5712,4596895382,760
Depreciation and amortization ($M)($M)
2221,1161,1322322201,3871,3971982021,3991,380895
Stock-based compensation ($M)($M)
1657512512715785134136157103161104
Deferred income taxes ($M)($M)
-291-1762-30-422-250-344-110-383-401-565-447
Change in trade receivables ($M)($M)
-1,093413-1,075222-515-1,308473-342-176486-433-342
Change in inventories ($M)($M)
-3118119240239288323681722806573-54
Change in accounts payable ($M)($M)
-70571-484-174589497-232-12264323-187156
Capital expenditures ($M)($M)
513712642436369411371257238230249248
Net cash used in investing activities ($M)($M)
-569-716-693-414-389-447-402-210-217-217-27,089-262
Proceeds from issuance of long-term debt ($M)($M)
03,9640000003,9961
Repayments of long-term debt ($M)($M)
-0833-01,5001,0002,500-02,2001,400-0-0750
Cash dividends paid ($M)($M)
1,3621,3581,2831,2821,2801,2791,2051,2101,2091,2081,1401,140
Net cash used in financing activities ($M)($M)
-1,4821,436-1,226-2,853-2,673-4,107-1,407-3,651-2,649-1,7082,754-2,005

26 chỉ số không có số liệu trong 12 quý gần nhất — .

In nghiêng là số StockData tự tính từ số đã báo cáo (rê chuột để xem công thức). Số có gạch chân chấm là số đọc từ câu chữ trong thông cáo kết quả và bản trình bày; rê chuột để xem đúng câu đó. Tick vào một dòng để thêm vào biểu đồ phía trên (tối đa 8 đường).

Phương pháp và các chỉ số bị loại
  • Các dòng ở Cốt lõi lấy từ thuyết minh bộ phận và phân tách doanh thu trong hồ sơ 10-K và 10-Q (XBRL), có liên kết tới từng hồ sơ. Số quý 4 bằng cả năm tài chính trừ chín tháng đầu (hiện bằng chữ in nghiêng).
  • Fiscal calendar: Amgen Inc. operates on a calendar fiscal year ending December 31 (FY2025 ended December 31, 2025; Q1 2026 ended March 31, 2026; Q2 2026 ended June 30, 2026). Amgen operates as a single global human therapeutics operating segment (Note 2), so commercial performance is tracked across 4 Therapeutic Franchises (General Medicine, Rare Disease, Inflammation, Oncology & Established Products) and 35+ commercialized brands disaggregated across United States (U.S.), Rest of World (ROW), and Worldwide (WW) net product sales.
  • Core commercial & R&D KPIs (Groups 1–6) cover: (1) Consolidated Revenues ($10,054M in Q2 2026 / $36,751M in FY25) and Total Product Sales ($9,567M in Q2 2026 / $35,147M in FY25 across U.S. $6,767M and ROW $2,800M in Q2 2026; U.S. volume +9% and ROW volume +8% YoY in Q2 2026) and General Medicine (Repatha $953M, EVENITY $714M, Prolia $759M in Q2 2026); (2) Rare Disease Franchise acquired via Horizon Therapeutics & ChemoCentryx (TEPEZZA $576M, KRYSTEXXA $400M, UPLIZNA $335M, TAVNEOS $150M, Ultra-Rare Products $168M in Q2 2026 including RAVICTI & PROCYSBI U.S./ROW breakdown); (3) Inflammation & Biosimilars (TEZSPIRE $486M, Otezla $491M, Enbrel $580M, PAVBLU $287M, AMJEVITA $155M, WEZLANA $14M in Q2 2026); (4) Oncology & Established Products (BLINCYTO $472M, IMDELLTRA $288M, Vectibix $338M, KYPROLIS $314M, Nplate $430M, XGEVA $352M, LUMAKRAS $111M, MVASI $153M, Aranesp $352M, Neulasta $92M, Parsabiv $90M in Q2 2026, plus Biosimilars in Other Products $372M in Q2 2026 / $1,422M in FY25); (5) Gross-to-Net (GTN) Sales Deductions Rollforward ($40,664M provisions / 54% of gross product sales and $6,661M ending reserve in FY25 across Rebates $30,275M, Chargebacks $9,081M & Other $1,308M), Top 3 U.S. Wholesalers (McKesson $20,986M / 27%, Cencora $19,708M / 25%, Cardinal Health $13,075M / 17% — combined 69% of worldwide gross revenues and 75% of net trade receivables in FY25), and Collaboration Profit Sharing (AstraZeneca TEZSPIRE, UCB EVENITY, Kyowa Kirin, BeiGene/BeOne); and (6) R&D by Clinical Stage ($7,232M total in FY25: Research & Early Pipeline $2,021M, Later-Stage Clinical Phase 2/3 $3,769M, Marketed Product Support $1,442M) and 8-K GAAP vs. Non-GAAP Reconciliations (48.4% Non-GAAP Operating Margin, $6.29 Non-GAAP Diluted EPS, $3,505M Free Cash Flow in Q2 2026).
  • Extended operational & ESG KPIs (Groups 7–11) cover: (7) Note 2 Segment Expenses (Manufacturing COGS $1,089M, Profit Share & Royalty COGS $817M, R&D Ex-Software $1,796M, Selling & Marketing $1,226M, G&A $539M in Q2 2026), Inventories by stage ($5,638M net at FY25), and Net PP&E by asset class & geography ($6,568M net at FY25, including $1,334M in Puerto Rico); (8) Goodwill ($18,625M at Q2 2026), Finite-Lived Intangible Assets ($22,256M net at Q2 2026 across Developed Technology, Licensing, Acquired R&D & Marketing-Related), Indefinite-Lived IPR&D ($1,225M), 5-year estimated amortization schedule, and Level 3 Contingent Consideration Rollforward; (9) Debt & 5-year maturity schedule ($53,015M total debt at Q2 2026), Operating Leases ($601M ROU assets / $617M lease liabilities at FY25), Capital Return ($2.52/sh dividend in Q2 2026), and SBC by award type; (10) Income Taxes, DTA/DTL breakdown & Unrecognized Tax Benefits Rollforward ($10,169M gross UTB balance & $5,088M accrued UTB interest/penalties at FY25 related to the IRS Puerto Rico transfer pricing dispute); and (11) Global Workforce (28,200 staff in FY25), CEO Pay Ratio (153:1 / $158,361 median employee in FY25), Form 11-K U.S. Plan ($8,963.48M net assets) & Puerto Rico Plan ($464.56M net assets at FY25), Patient Access ($3.2B U.S. Safety Net Foundation & $232M LMIC donations in FY25), Workplace Safety (0.21 staff TRIR in FY25), and Scope 1, 2 & 3 GHG Emissions, Energy, Water & Waste.
  • No parent-only standalone financial statements exist under U.S. GAAP (Form 10-K omits Schedule I), so no Consolidated − Standalone subtraction is performed. All values are strictly as published (with verbatim quotes on hover for text-extracted metrics; bound disclosures are excluded from table cells). The only arithmetic shown in table cells is period splitting (Q4 = full year − 9M; Q2 = 6M − Q1; Q3 = 9M − 6M), displayed in italic with the formula.

Không hiện vì thiếu các kỳ gần đây (3)

  • Human Capital, CEO Pay Ratio (DEF 14A), Form 11-K U.S. & Puerto Rico Retirement Plans, Patient Access & Environmental Sustainability › Workplace Safety — Staff Total Recordable Incident Rate (TRIR per 200,000 hours) › Environmental Notices of Violation (NOVs)
  • Industry & Macro Healthcare Benchmarks (FRED) & Core Financial Statements (DB) › Income Statement — Total revenues ($M) › Gross profit ($M)
  • Industry & Macro Healthcare Benchmarks (FRED) & Core Financial Statements (DB) › Balance Sheet — Total assets ($M) › Current portion of long-term debt ($M)

Dữ liệu cập nhật 2026-10-28.

Mỗi KPI một trang riêng

Đầy đủ lịch sử, biểu đồ, nguồn và cách trích dẫn cho từng chỉ số

Oncology & Hematology Franchise (BLINCYTO, IMDELLTRA, Vectibix, KYPROLIS, Nplate, XGEVA, LUMAKRAS) & Established Products

Tài liệu nguồn mới nhất

Các tài liệu được trích nhiều nhất cho số liệu mới nhất của Amgen

See a number that looks wrong?